Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo

Cancer Prevention Research

Volumn 4, Issue 5, 2011, Pages 666-673

  Huang, Shaoyi ^a   Ren, Xiaoyang ^a   Wang, Lai ^b   Zhang, Ling ^a   Wu, Xiangwei ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Joyant Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLICE INHIBITORY PROTEIN; JP 1584; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOMA CELL; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TARGET CELL DESTRUCTION;

ANIMALS; APOPTOSIS; BIOMIMETICS; CASPASES; FEMALE; GENES, LETHAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MICE; MITOCHONDRIAL PROTEINS; MUTATION; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 79955872479     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0235     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. World Health Organization. Cancer. 2009. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/index.html.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
4. Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers. Cancer 1996;78:1004-10. (Pubitemid 26284865)
5. Downward J. Signal transduction. New exchange, new target. Nature 1998;396:416-7.
6. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000;10:147-54.
7. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998;273:19925-8.
8. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
9. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. Cosmic 2005. Br J Cancer 2006;94:318-22.
10. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol 1997;181:401-4. (Pubitemid 27223525)
11. Keith RL. Chemoprevention of lung cancer. Proc Am Thorac Soc 2009;6:187-93.
12. Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res 2010;3:148-59.
13. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90. (Pubitemid 26175834)
14. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
15. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-9. (Pubitemid 38987058)
16. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000;74:281-6. (Pubitemid 30182582)
17. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39:1462-75. (Pubitemid 47031030)
18. Koschny R, Walczak H, Ganten TM. The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 2007;85:923-35. (Pubitemid 47282789)
19. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
20. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-8. (Pubitemid 32905115)
21. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5.
22. Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 2006;17:313-21. (Pubitemid 43160123)
23. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-5. (Pubitemid 46706887)
24. Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2001;2:REVIEWS3009.
25. Dean EJ, Ranson M, Blackhall F, Dive C. X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opin Ther Targets 2007;11:1459-71. (Pubitemid 350200481)
26. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
27. Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004;29:486-94.
28. Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, et al. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 464:1058-61.
29. Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clin Cancer Res 2005;11:4278-81. (Pubitemid 40825613)
30. Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 2006;103:16472-7. (Pubitemid 44715220)
31. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005;310:306-10. (Pubitemid 41457195)
32. Ren X, Xu Z, Myers JN, Wu X. Bypass NFkappaB-Mediated Survival Pathways by TRAIL and Smac. Cancer Biol Ther 2007;6:1031-5. (Pubitemid 351574953)
33. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003;115:61-70. (Pubitemid 37255318)
34. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-8. (Pubitemid 34008190)
35. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005;65:10280-8. (Pubitemid 41743720)
36. Dobzhansky T. Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 1946;31:269-90.
37. Lucchesi JC. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. Genetics 1968;59:37-44.
38. Guarente L. Synthetic enhancement in gene interaction: a genetic tool come of age. Trends Genet 1993;9:362-6. (Pubitemid 23296291)
39. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
40. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009;8:3112-9.